WUHAN EASY DIAGNOSIS BIOMEDICINE CO.,LTD.

Wuhan Easy Diagnosis Biomedicine Co.,Ltd.

Equities

002932

CNE1000033Q7

Medical Equipment, Supplies & Distribution

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-07-04 pm EDT			5-day change	1st Jan Change
16.82 ^CNY	+2.69%		+0.06%	-26.77%

Jul. 02	Tranche Update on Wuhan Easy Diagnosis Biomedicine Co.,Ltd.'s Equity Buyback Plan announced on March 28, 2024.	CI
May. 22	Wuhan Easy Diagnosis Biomedicine Co.,Ltd. Announces Final Cash Dividend Plan on A Shares for the Year 2023, Payable on Ma 28, 2024	CI

Tranche Update on Wuhan Easy Diagnosis Biomedicine Co.,Ltd.'s Equity Buyback Plan announced on March 28, 2024.

July 02, 2024 at 03:39 pm EDT

From April 1, 2024 to June 30, 2024, the company has repurchased 7,849,718 shares, representing 3.38% for CNY 153.67 million. With this, the company has completed the repurchase of 8,349,718 shares, representing 3.59% for CNY 163.61 million under the buyback announced on March 28, 2024.

Latest news about Wuhan Easy Diagnosis Biomedicine Co.,Ltd.

Tranche Update on Wuhan Easy Diagnosis Biomedicine Co.,Ltd.'s Equity Buyback Plan announced on March 28, 2024.	Jul. 02	CI
Wuhan Easy Diagnosis Biomedicine Co.,Ltd. Announces Final Cash Dividend Plan on A Shares for the Year 2023, Payable on Ma 28, 2024	May. 21	CI
Wuhan Easy Diagnosis Biomedicine Co.,Ltd. Approves the Cash Dividend for the Year 2023	May. 20	CI
Wuhan Easy Diagnosis Biomedicine Co.,Ltd. Proposes Final Cash Dividend for Year 2023	Apr. 26	CI
Tranche Update on Wuhan Easy Diagnosis Biomedicine Co.,Ltd.'s Equity Buyback Plan announced on March 28, 2024.	Mar. 31	CI
Wuhan Easy Diagnosis Biomedicine Co.,Ltd. commences an Equity Buyback Plan for CNY 350 million worth of its shares, under the authorization approved on March 18, 2024.	Mar. 27	CI
Wuhan Easy Diagnosis Biomedicine Co.,Ltd. authorizes a Buyback Plan.	Feb. 29	CI
Wuhan Easy Diagnosis Biomedicine Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-30	CI
Wuhan Easy Diagnosis Biomedicine Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-30	CI
Wuhan Easy Diagnosis Biomedicine Co.,Ltd. Announces Final Cash Dividend on A Shares for the Year 2022, Payable on 06 June 2023	23-05-30	CI
Wuhan Easy Diagnosis Biomedicine Co.,Ltd. Approves Dividend for 2022	23-05-15	CI
Wuhan Easy Diagnosis Biomedicine Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-26	CI
Wuhan Easy Diagnosis Biomedicine Co.,Ltd. Proposes Profit Distribution for 2022	23-04-21	CI
Wuhan Easy Diagnosis Biomedicine Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-19	CI
China stocks retreat on concerns of surging COVID cases	22-12-12	RE
China stocks retreat on concerns of rising COVID cases	22-12-11	RE
Wuhan Easy Diagnosis Biomedicine Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-26	CI
Wuhan Easy Diagnosis Biomedicine Co.,Ltd. Announces Executive Elections	22-10-24	CI
Wuhan Easy Diagnosis Biomedicine Co.,Ltd.(XSEC:002932) added to S&P Global BMI Index	22-09-19	CI
Wuhan Easy Diagnosis Biomedicine Co.,Ltd. Announces Interim Profit Distribution Plan to Be Implemented on A Shares for the Year 2022, Payable on 21 September 2022	22-09-14	CI
Wuhan Easy Diagnosis Biomedicine Co.,Ltd. Approves Interim Cash Dividend for 2022	22-09-13	CI
Zhuhai Digifluidic Biotechnology Co., Ltd. announced that it has received CNY 100.596565 million in funding from Wuhan Easy Diagnosis Biomedicine Co.,Ltd., Guangzhou Funway Asset Management Co., Ltd., Guangzhou Huiju Xinxing Equity Investment Partnership	22-09-12	CI
Zhuhai Digifluidic Biotechnology Co. announced that it expects to receive CNY 0.747 million in funding from Wuhan Easy Diagnosis Biomedicine Co.,Ltd., Guangzhou Funway Asset Management Co., Ltd., Guangzhou Huiju Xinxing Equity Investment Partnership and another investor	22-09-08	CI
Wuhan Easy Diagnosis Biomedicine Co.,Ltd. Announces the Profit Distribution Proposal for the First Half of 2022	22-08-25	CI
Wuhan Easy Diagnosis Biomedicine Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-07-29	CI

Chart Wuhan Easy Diagnosis Biomedicine Co.,Ltd.

Duration

Period

Chart Wuhan Easy Diagnosis Biomedicine Co.,Ltd.

More charts

Company Profile

Wuhan Easy Diagnosis Biomedicine Co., Ltd. is a China-based company which is mainly engaged in research and development, manufacture and sales of Point of Care Testing (POCT) rapid diagnostic reagents and quick testing instruments. The Company's main products are POCT rapid diagnostic reagents, which can be divided into six categories: infectious diseases, cardiovascular and cerebrovascular diseases, kidney diseases, diabetes, gynecology and eugenics, and health checkups. The Company's main products are mainly used in domestic hospitals, health service centers, community clinics, medical examination centers and other medical institutions.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-08-28 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Sector Diagnostic & Testing Substances

	1st Jan change	Capi.
WUHAN EASY DIAGNOSIS BIOMEDICINE CO.,LTD.	-26.77%	538M
BIOMÉRIEUX	-6.61%	12.02B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-19.37%	6.81B
DIASORIN S.P.A.	+6.63%	5.74B
LANTHEUS HOLDINGS, INC.	+27.24%	5.47B
AUTOBIO DIAGNOSTICS CO., LTD.	-21.19%	3.59B
ANDON HEALTH CO., LTD.	+6.64%	2.56B
MYRIAD GENETICS, INC.	+30.09%	2.25B
10X GENOMICS, INC.	-66.53%	2.24B
VITROLIFE AB	-12.28%	2.21B

Diagnostic & Testing Substances